Weekly Research Analysts’ Ratings Updates for bluebird bio (BLUE)

A number of research firms have changed their ratings and price targets for bluebird bio (NASDAQ: BLUE):

• 11/18/2024 – bluebird bio is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 11/15/2024 – bluebird bio was downgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “underweight” rating.
• 11/15/2024 – bluebird bio had its “sector perform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $4.00 price target on the stock.
• 11/15/2024 – bluebird bio had its price target lowered by analysts at Barclays PLC from $4.00 to $2.00. They now have an “overweight” rating on the stock.
• 11/15/2024 – bluebird bio was downgraded by analysts at Bank of America Co. from a “buy” rating to a “neutral” rating. They now have a $0.50 price target on the stock, down previously from $3.00.
• 11/10/2024 – bluebird bio is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 11/2/2024 – bluebird bio is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 10/25/2024 – bluebird bio is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 10/17/2024 – bluebird bio is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 10/5/2024 – bluebird bio is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 9/27/2024 – bluebird bio is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 9/25/2024 – bluebird bio had its price target lowered by analysts at Wells Fargo & Company from $3.00 to $2.00. They now have an “equal weight” rating on the stock.

bluebird bio Stock Down 8.4 %

BLUE stock opened at $0.31 on Wednesday. The company has a current ratio of 0.51, a quick ratio of 0.33 and a debt-to-equity ratio of 0.37. The firm has a 50 day simple moving average of $0.48 and a 200-day simple moving average of $0.78. The company has a market capitalization of $59.32 million, a P/E ratio of -0.16 and a beta of 0.76. bluebird bio, Inc. has a twelve month low of $0.30 and a twelve month high of $5.53.

bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings data on Friday, September 13th. The biotechnology company reported ($0.36) earnings per share for the quarter. The company had revenue of $18.57 million for the quarter. bluebird bio had a negative return on equity of 322.46% and a negative net margin of 565.74%. On average, equities research analysts predict that bluebird bio, Inc. will post -1.41 earnings per share for the current fiscal year.

Institutional Trading of bluebird bio

Several institutional investors and hedge funds have recently bought and sold shares of BLUE. Allegheny Financial Group LTD acquired a new position in shares of bluebird bio in the 2nd quarter worth approximately $25,000. Price T Rowe Associates Inc. MD boosted its holdings in bluebird bio by 113.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 54,714 shares of the biotechnology company’s stock worth $71,000 after purchasing an additional 29,113 shares during the period. Bayesian Capital Management LP bought a new stake in bluebird bio during the first quarter valued at $52,000. American International Group Inc. raised its holdings in shares of bluebird bio by 77.4% during the first quarter. American International Group Inc. now owns 94,371 shares of the biotechnology company’s stock worth $121,000 after purchasing an additional 41,177 shares during the period. Finally, State Street Corp boosted its holdings in shares of bluebird bio by 1.1% in the 3rd quarter. State Street Corp now owns 3,841,923 shares of the biotechnology company’s stock valued at $1,996,000 after buying an additional 43,382 shares during the period. Institutional investors and hedge funds own 87.43% of the company’s stock.

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.